Source:http://linkedlifedata.com/resource/pubmed/id/20534261
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2010-6-10
|
pubmed:abstractText |
Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) is almost universal; cirrhosis develops in up to 30% of cases. Currently there is interest in the midterm outcomes of HCV patients with concomitant hepatitis B virus (HBV) infection among OLT recipients. We therefore retrospectively analyzed our database of patients who underwent OLT for HCV-HBV-related cirrhosis. Between April 1992 and December 2008, 350 patients underwent OLT, including 20 (5.7%) transplanted for HBV-HCV cirrhosis. We assessed patient and graft survivals at 1 and 5 years, as well as the progression of fibrosis. Protocol liver biopsies were available yearly after OLT. The survival curves were analyzed by the Kaplan-Meier approach and chronic hepatitis evaluated according to the Ishak scoring system. At a median follow-up of 68.4 +/- 53 months, the 1- and 5-year patient and graft survival rates were 80% and 70%, respectively. The 5-year fibrosis progression rate was 0.17 +/- 0.08 units of fibrosis. The only patient who developed histologic cirrhosis within 10 years of follow-up showed a lamivudine-resistant HBV recurrence. Patients transplanted for HBV-HCV coinfection showed a lower fibrosis progression rate compared with HCV monoinfected subjects.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Azathioprine,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulins,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus,
http://linkedlifedata.com/resource/pubmed/chemical/hepatitis B hyperimmune globulin
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1873-2623
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright (c) 2010. Published by Elsevier Inc.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
42
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1200-3
|
pubmed:meshHeading |
pubmed-meshheading:20534261-Azathioprine,
pubmed-meshheading:20534261-Cyclosporine,
pubmed-meshheading:20534261-Graft Survival,
pubmed-meshheading:20534261-Hepatitis B,
pubmed-meshheading:20534261-Hepatitis C,
pubmed-meshheading:20534261-Humans,
pubmed-meshheading:20534261-Immunoglobulins,
pubmed-meshheading:20534261-Immunosuppressive Agents,
pubmed-meshheading:20534261-Liver Transplantation,
pubmed-meshheading:20534261-Prednisone,
pubmed-meshheading:20534261-Retrospective Studies,
pubmed-meshheading:20534261-Survival Rate,
pubmed-meshheading:20534261-Tacrolimus,
pubmed-meshheading:20534261-Treatment Outcome
|
pubmed:year |
2010
|
pubmed:articleTitle |
Liver transplantation for hepatitis B and C virus-related cirrhosis: mid-term results.
|
pubmed:affiliation |
Transplant Unit, Department of Surgery, University of Rome Tor Vergata, Rome, Italy. tomanzia@libero.it
|
pubmed:publicationType |
Journal Article
|